| Literature DB >> 34944230 |
Stuart J Patterson1, Charlene Clarke2, Tim H Clutton-Brock3,4, Michele A Miller2, Sven D C Parsons2, Dirk U Pfeiffer1,5, Timothée Vergne6, Julian A Drewe1.
Abstract
Diagnostic tests are used to classify individual animals' infection statuses. However, validating test performance in wild animals without gold standard tests is extremely challenging, and the issue is further complicated in chronic conditions where measured immune parameters vary over time. Here, we demonstrate the value of combining evidence from different diagnostic approaches to aid interpretation in the absence of gold standards, large sample sizes, and controlled environments. Over a two-year period, we sampled 268 free-living meerkats (Suricata suricatta) longitudinally for Mycobacterium suricattae (a causative agent of tuberculosis), using three ante-mortem diagnostic tests based on mycobacterial culture, and antigen-specific humoral and cell-mediated immune responses, interpreting results both independently and in combination. Post-mortem cultures confirmed M. suricattae infection in 22 animals, which had prior ante-mortem information, 59% (13/22) of which were test-positive on a parallel test interpretation (PTI) of the three ante-mortem diagnostic assays (95% confidence interval: 37-79%). A similar ability to detect infection, 65.7% (95% credible interval: 42.7-84.7%), was estimated using a Bayesian approach to examine PTI. Strong evidence was found for a near doubling of the hazard of death (Hazard Ratio 1.75, CI: 1.14-2.67, p = 0.01), associated with a positive PTI result, thus demonstrating that these test results are related to disease outcomes. For individual tests, small sample sizes led to wide confidence intervals, but replication of conclusions, using different methods, increased our confidence in these results. This study demonstrates that combining multiple methodologies to evaluate diagnostic tests in free-ranging wildlife populations can be a useful approach for exploiting such valuable datasets.Entities:
Keywords: diagnostics; interpretation; meerkats; tuberculosis; wildlife
Year: 2021 PMID: 34944230 PMCID: PMC8698085 DOI: 10.3390/ani11123453
Source DB: PubMed Journal: Animals (Basel) ISSN: 2076-2615 Impact factor: 3.231
Inclusion criteria and justification for each analysis conducted as part of this study.
| Aim of the Analysis | Approach Used | Inclusion Criteria | Time Period | References |
|---|---|---|---|---|
| 1. To determine the ability of each testing regime to correctly identify infected animals (test sensitivity) | Comparison with a reference test | All animals from which | September 2014-September 2016 inclusive (Full) | [ |
| 2. To determine each testing regime’s ability to correctly identify animals as infected (sensitivity) or uninfected (specificity) | Latent Class Analysis | The first sample collected for each individual was used. The time-period was limited to minimise the impact of changes over time on prevalence. | September 2014–March 2015 inclusive | [ |
| 3. To quantify the agreement between the results from different tests | Calculation of the kappa statistic | All sampling events where there was more than one test were used. | Full | [ |
| 4. To investigate whether test results were predictive of mortality | Survival analysis of time to death | All samples collected over the study period from wild individuals were used. | Full | [ |
| 5. To investigate whether test results were predictive of clinical signs of disease | Survival analysis of time to showing clinical signs | All samples collected over the study period from wild individuals were used. | Full | [ |
| 6. To investigate whether individuals’ test results fluctuate over time | Analysis of consistency over time | All individuals sampled on more than one occasion were included. | Full | - |
| 7. To investigate whether test result is influenced by age | Analysis for association with age | All samples from individuals with a known date of birth were included. | Full | - |
| 8. To Investigate whether test results were detecting infection more often in the most susceptible animals | Analysis for association with risk | Only the first sample from individuals with a known date of birth were included. The time-period was limited to minimise the impact of changes over time. | September 2014–March 2015 inclusive | [ |
Variables found to have a significance of p < 0.2 in the univariable analysis were incorporated into a multivariable analysis in a forward-stepwise process, with each addition to the model compared to the simpler version using analysis of deviance for a Cox model [26]. A gamma-frailty term was included for the social group in which the individual was resident [27].
Sensitivity estimates for three diagnostic tests, when used alone and in combination, compared to a reference test. Ante-mortem test results are presented for 23 individuals that were later confirmed as definitively infected by post-mortem culture. Animals were tested using tracheal wash culture, DPP assay, and IFNγ inducible-protein 10 release assays (IPRA). All 23 animals were tested at the point of euthanasia, and results from previous sampling points are provided at time points relative to euthanasia. An animal was considered positive on parallel interpretation if it had a positive result on at least one of the three individual tests. A positive status to the “ever positive” interpretation was given if any single individual test was positive either at that time point or ever in the animal’s test history.
| Individual Test Interpretations | Multiple Test Interpretations | |||||
|---|---|---|---|---|---|---|
| Time before Euthanasia (days) |
| Serology (DPP) | Cell-Mediated Immunity (IPRA) | Tracheal Wash Culture | Parallel | Ever Positive |
| 0 | 23 | 3/22 | 10/22 | 3/23 | 13/22 | 18/22 |
| 1–90 | 10 | 0/10 | 4/10 | 0/10 | 4/9 | 6/9 |
| 91–180 | 7 | 0/7 | 4/7 | 0/7 | 4/7 | 5/7 |
| 181–365 | 11 | 0/11 | 1/8 | 0/11 | 1/8 | 2/8 |
| >365 | 11 | 0/11 | 1/8 | 0/11 | 1/8 | 1/8 |
* 95CI, 95% confidence interval. DPP: dual-path platform; IPRA: IP-10 release assays.
Bayesian sensitivity and specificity estimates for three diagnostic tests, when used alone and in combination, in the absence of a reference test. The model for these estimates was based upon tests taken from three populations; a captive population with assumed zero prevalence (n = 10), the wild population of unknown prevalence (n = 171), and a group of post-mortem confirmed cases with 100% prevalence (n = 11). The dual-path platform VetTB (tuberculosis) assay was used for serology, an IP-10 (inducible-protein 10) release assay for the test of cell-mediated immunity, and a tracheal wash sample was provided for culture. The parallel interpretation was considered positive if one or more of the individual tests was positive. The model estimated a prevalence of 32.2% (95% confidence interval: 4.8–69.2%) in the wild population. Convergence of the Bayesian model was considered good.
| Serology (DPP) | Cell-Mediated Immunity (IPRA) | Tracheal Wash Culture | Parallel Interpretation | |
|---|---|---|---|---|
| Sensitivity (%, Credible interval) | 12.0 (4.0–33.6) | 58.6 (35.1–80.6) | 2.2 (0.1–10.9) | 65.7 (42.7–84.7) |
| Specificity (%, Credible interval) | 97.9 (92.8–99.9) | 85.0 (68.4–99.4) | 99.2 (95.7–99.9) | 81.9 (65.2–96.7) |
DPP: dual-path platform; IPRA: IP-10 release assays.
Survival analysis of time to death. Results of univariable and multivariable analysis using time-dependent Cox regression. Hazards were calculated for the likelihood of a meerkat being lost from the study population. Model (a) includes all individuals (of whom 118 experienced the event, death), and on the following page, model (b), excludes euthanased individuals.
|
| |||||
|
|
|
|
| ||
| Dominance | No | 0.966 | |||
| Yes | 0.99 | 0.64–1.53 | |||
| Sex | Female | 0.813 | |||
| Male | 1.05 | 0.711.54 | |||
| Age | <6 months | 0.678 | |||
| 6–12 months | 1.03 | 0.55–1.92 | |||
| >12 months | 0.85 | 0.49–1.45 | |||
| Serology | Neg a | 0.039 | |||
| Pos b | 2.44 | 1.04–5.70 | |||
| Cell-Mediated immunity | Neg a | 0.107 | |||
| Pos b | 1.45 | 0.92–2.28 | |||
| Culture | Neg a | 0.013 | |||
| Pos b | 14.84 | 1.76–125.5 | |||
| Parallel | Neg a | 0.010 | |||
| Pos b | 1.75 | 1.14–2.67 | |||
| Multivariable | Hazard Ratio | 95% Confidence Interval | Likelihood ratio for model, | ||
| Serology + Frailty Sampling group | Neg a | <0.0001 | |||
| Pos b | 1.29 | 0.51–3.31 | 0.59 | ||
| Variance of frailty term | 1.126 | ||||
| Cell-Mediated immunity + Frailty Social group | Neg a | <0.0001 | |||
| Pos b | 1.10 | 0.65–1.87 | 0.72 | ||
| Variance of frailty term | 1.939 | ||||
| Culture + Frailty Social group | Neg a | <0.0001 | |||
| Pos b | 1.92 | 0.22–16.60 | 0.55 | ||
| Variance of frailty term | 1.075 | ||||
| Parallel + Frailty Social group | Neg a | <0.0001 | |||
| Pos b | 1.30 | 0.80–2.11 | 0.29 | ||
| Variance of frailty term | 1.028 | ||||
| Model b–Excluding euthanised animals ( | |||||
|
| Hazard Ratio | 95% Confidence Interval | |||
| Dominance | No | 0.780 | |||
| Yes | 1.06 | 0.69–1.65 | |||
| Sex | F | 0.820 | |||
| M | 1.05 | 0.70–1.56 | |||
| Age | <6 months | 0.897 | |||
| 6–12 months | 0.93 | 0.48–1.79 | |||
| >12 months | 0.88 | 0.51–1.53 | |||
| Serology | Neg a | 0.116 | |||
| Pos b | 2.09 | 0.83–5.27 | |||
| CMI | Neg a | 0.09 | |||
| Pos b | 1.48 | 0.93–2.34 | |||
| Culture | Neg a | 0.008 | |||
| Pos b | 18.66 | 2.13–163.60 | |||
| Parallel | Neg a | 0.011 | |||
| Pos b | 1.75 | 1.14–2.68 | |||
|
| Hazard Ratio | 95% Confidence Interval | Likelihood ratio for model, | ||
| Serology + Frailty Sampling group | Neg a | <0.0001 | |||
| Pos b | 1.04 | 0.38–2.86 | 0.94 | ||
| Variance of frailty term | 1.126 | ||||
| CMI + Frailty Social group | Neg a | <0.0001 | |||
| Pos b | 1.17 | 0.68–1.99 | 0.57 | ||
| Variance of frailty term | 1.809 | ||||
| Culture + Frailty Social group | Neg a | <0.0001 | |||
| Pos b | 2.37 | 0.26–21.39 | 0.44 | ||
| Variance of frailty term | 1.013 | ||||
| Parallel + Frailty Social group | Neg a | <0.0001 | |||
| Pos b | 1.33 | 0.81–2.17 | 0.26 | ||
| Variance of frailty term | 0.972 | ||||
a Neg, Negative. b Pos, Positive.
Figure 1Parallel testing (using culture, serology, and a test of cell-mediated immunity) of 44 individuals tested on multiple occasions. Each row represents an individual animal, and each circle, a separate sampling point. Positive tests are shown in red, and negative in blue. The sampling points are shown in the order in which they were collected, with the earliest on the left, and the most recent sample shown on the right. Although the time between sampling points varied, the minimum interval between two samples was three months. Nine individuals changed from positive to negative test status within the two-year study period; three of these subsequently reverted to a positive test status.
Figure 2Association between predicted risk of infection and diagnostic test results. The percentage of animals testing positive to each test is shown in each of four risk categories, with 95% confidence intervals. Risk categories are defined by age (animals aged over 2 years were categorised as Old, and those below 2 years as Young) and social group history of disease (groups having had clinical cases being “Pos”, and those without being “Neg”). Culture results are based upon a tracheal wash culture, cell-mediated immunity (CMI) results are those from the IPRA (IP-10 release assays), and serology results are based upon the DPP (dual-path platform) assay. A test was considered positive on parallel test interpretation if it tested positive to one or more of the individual tests. The results of tests of cell-mediated immunity and the parallel test interpretation reflect an individual’s risk of being infected, whereas no difference is seen between risk groups when testing with serology or culture. As indicated by the *, for both the CMI and the parallel tests, there is a significant difference (p < 0.05) between the highest risk group (Old/Pos) and both the Young/Pos and the Young/Neg groups.